Abstracts Archive - Page 561 of 1683 - ATC Abstracts

2019 American Transplant Congress
Assessment Of Glomerular Filtration Rate Among Lung Transplant Candidates
S. Akkina¹, S. Hou², D. Jain Arwindekar², A. Desai²
¹Loyola University Medical Center, Maywood, IL, ²Medicine, Loyola University Medical Center, Maywood, IL
*Purpose: Assessment of kidney function in lung transplant candidates is difficult due to cachexia prior to transplant. Measured glomerular filtration rate (GFR) studies are useful…
2019 American Transplant Congress
The Molecular Features of Chronic Lung Allograft Dysfunction (CLAD) in Transbronchial and Endobronchial Mucosa Biopsies
M. D. Parkes¹, K. M. Halloran¹, J. Chang², P. F. Halloran and the INTERLUNG study group¹
¹University of Alberta, Edmonton, AB, Canada, ²ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD), the major long-term problem in lung transplantation, requires new strategies for prevention and management. However, CLAD is infrequently diagnosed…
2019 American Transplant Congress
Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients
F. J. Marco Canosa¹, K. Brizendine², H. Hassouna³
¹Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ³Infectious Disease, Spectrum Health Infectious Disease, Grand Rapids, MI
*Purpose: Cystic fibrosis (CF) patients exhibit unique pharmacokinetic principles. Azole antifungals show marked inter- and intra-patient variability. We aimed to improve itraconazole (ITR) use and…
2019 American Transplant Congress
Simulation of DSA-Free Lung Allocation
M. Skeans¹, J. Pyke¹, K. Audette¹, R. Lehman², K. Uccellini², K. M. Chan³, E. D. Lease⁴, R. Daly⁵, M. Valapour⁶
¹SRTR, Minneapolis, MN, ²OPTN, Richmond, VA, ³Univ. of Michigan, Ann Arbor, MI, ⁴Univ. of WA, Seattle, WA, ⁵Mayo Clinic, Rochester, MN, ⁶Cleveland Clinic Foundation, Cleveland, OH
*Purpose: In November 2017, the OPTN Executive Committee removed donation service area (DSA) as the first unit of adult donor lung allocation, replacing it with…
2019 American Transplant Congress
Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant
S. Marshall¹, K. Tsveybel¹, S. Boukedes¹, P. Burkett², R. Chepuri², A. Coppolino³, M. Divo², S. El-Chemaly², S. Keller², J. Kennedy², H. Mallidi³, G. Mody³, T. Thaniyavarn², A. Trindade², K. Townsend¹, H. Goldberg²
¹Lung Transplant, Brigham & Women's Hospital, Boston, MA, ²Pulmonary Division, Brigham & Women's Hospital, Boston, MA, ³Thoracic Surgery, Brigham & Women's Hospital, Boston, MA
*Purpose: Thromboembolic complications are common post-transplant leading to significant morbidity. We instituted early enoxaparin prophylaxis (ppx) in lung transplant recipients (LTR) due to an observed…
2019 American Transplant Congress
Lung Transplantation in the Elderly Patients with Multi-Comorbidities
N. Shigemura, Y. Toyoda
Temple University Health System / Lewis Katz School of Medicine, Philadelphia, PA
*Purpose: Recently there is an outstanding steadily increase in elderly patients above 70 years old who are referred to our center as potential candidates for…
2019 American Transplant Congress
Simulation vs. Reality: 250NM as First Unit of Lung Allocation
M. Skeans¹, J. Pyke¹, C. Lehr², R. Lehman³, K. Uccellini³, K. M. Chan⁴, E. D. Lease⁵, R. Daly⁶, M. Valapour²
¹SRTR, Minneapolis, MN, ²Cleveland Clinic Foundation, Cleveland, OH, ³OPTN, Richmond, VA, ⁴Univ. of Michigan, Ann Arbor, MI, ⁵Univ. of WA, Seattle, WA, ⁶Mayo Clinic, Rochester, MN
*Purpose: In November 2017, the OPTN Executive Committee removed donation service area as the first unit of donor allocation, replacing it with a circle of…
2019 American Transplant Congress
Synergistic Effect of HLA Eplet Mismatch Load and CMV Viremia on Clinical Antibody-Mediated Rejection in Lung Transplantation
Y. Im¹, S. Yeramaneni², Y. Yim³, J. Dodderer⁴, M. Askar¹, H. J. Huang⁵
¹Baylor University Medical Center, Dallas, TX, ²Baylor Scott & White Health, Dallas, TX, ³Ross University School of Medicine, Portsmouth, Dominica, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Houston Methodist Hospital, Houston, TX
*Purpose: De novo donor specific antibodies (dnDSA) occur in up to 50% of lung transplant (LUTX) recipients within one year and are associated with increased…
2019 American Transplant Congress
Comparison of Basiliximab and Alemtuzumab for Lung Transplant Induction
S. Mietz¹, D. Roe², E. Lushin¹, E. Anderson¹, C. Hage²
¹Pharmacy, Indiana University Health, Indianapolis, IN, ²Pulmonary Critical Care, Indiana University Health, Indianapolis, IN
*Purpose: Compare alemtuzumab and basiliximab used for lung transplant in terms of rejection, CLAD, and mortality.*Methods: A retrospective review of lung transplants performed between 2010…
2019 American Transplant Congress
Pediatric Heart and Lung Graft Loss during the “High-Risk Age Window”
J. Long¹, J. Motter¹, K. R. Jackson¹, M. Kosztowski¹, B. Orandi², X. Luo¹, K. Van Arendonk³, A. Massie¹, E. Bush¹, R. S. Higgins¹, D. L. Segev¹, J. M. Garonzik-Wang¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²University Of Alabama at Birmingham, Birmingham, AL, ³Children’s Hospital of Wisconsin-Milwaukee Campus, Milwaukee, WI
*Purpose: Pediatric kidney transplant recipients experience a high-risk age window of increased graft loss during late adolescence and early adulthood (17-24 years), termed emerging adulthood.…